SEC Form 4 · accession 0001445064-16-000201
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Coleman N Lannum III
Officer — Sr.VP, Investor Strategy & IRO
Period of report
Feb 8, 2016
Accepted (ET)
Feb 9, 2016 · 8:59 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 8, 2016 | P | 800 | $66.37 | A | 16,740 | D | |
| Ordinary Shares | holding | — | — | — | 900 | I | By wife | |
| Ordinary Shares | holding | — | — | — | 75 | I | By son (M) | |
| Ordinary Shares | holding | — | — | — | 45 | I | By son (R) | |
| Ordinary Shares | holding | — | — | — | 45 | I | By son (S) | |
| Ordinary Shares | holding | — | — | — | 20 | I | By mother |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $65.88 to $66.66, inclusive. Mr. Lannum will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
- F2Includes 35 shares acquired between January 7, 2016 and February 5, 2016, under the Mallinckrodt employee stock purchase plan.